Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
On September 10, 2026, India Ratings and Research upgraded Glenmark Pharmaceuticals Ltd's long-term bank loans to 'IND AA+' with a Stable Outlook, from 'IND AA'. Short-term loans were affirmed at 'IND A1+'. This upgrade was influenced by the company's recognition of USD560 million in revenue from a July 2025 licensing agreement with AbbVie Inc., which contributed to Glenmark achieving zero gross debt by the fiscal year ended March 31, 2026. The agency also assigned ratings to new bank loan facilities totaling INR42 billion.
Glenmark announced the commercial launch of RYALTRIS® Nasal Spray in Brazil on September 11, 2026, for treating moderate to severe allergic rhinitis. This product, already approved in 57 global markets, is the first olopatadine-containing intranasal combination therapy available in Brazil. Additionally, Glenmark Pharmaceuticals Inc., USA, launched Calcium Gluconate Injection USP in multiple presentations on August 21, 2026. The US market for these presentations achieved annual sales of approximately $69.9 million for the 12 months ending June 2026.
During the AGM on September 11, 2026, shareholders approved the financial statements for the fiscal year ended March 31, 2026, and declared a dividend of INR 2.50 per equity share. Mrs. Blanche Saldanha was re-appointed as a Non-Executive Director, and the remuneration for the Cost Auditor for the year ending March 31, 2027, was ratified. All resolutions passed with over 95% approval.
As of September 18, 2026, Glenmark's stock has shown positive returns over several periods. Year-to-date, the return was 0.21. Over the last 3 months, the return was 0.14, and over the last 6 months, it was 0.12. The stock also saw a return of 0.16 over the last year and 0.52 since the start of its trading history.
On a daily basis, technical indicators suggest a bullish trend, with the Supertrend indicator at 2299.3 and the 20-day Exponential Moving Average (EMA) at 2410.22, showing upward momentum. However, the monthly trend analysis indicates a bearish direction, with the Supertrend at 2,665.43 and a high ADX value of 59.73, suggesting strong but potentially volatile market conditions.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 14 candles
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Primary driver: Price swings are higher than typical
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Upward price movement of 2.57 standard deviations recorded on 2026-08-20.
Unusual market activity that may warrant review of the underlying price, volume, or news context.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Upward price movement of 2.82 standard deviations recorded on 2026-07-29.
Unusual market activity that may warrant review of the underlying price, volume, or news context.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹4,018.48 crore | ₹3,770.59 crore | ₹3,900.62 crore | PEAK₹6,046.87 crore | ₹3,264.44 crore |
| Finance Costs | ₹54 crore | ₹42.60 crore | ₹41.43 crore | PEAK₹66.46 crore | ₹58.23 crore |
| Other Expenses | ₹1,033.19 crore | ₹948.27 crore | ₹894.37 crore | PEAK₹1,336.56 crore | ₹905.59 crore |
| Profit Before Exceptional Items And Tax | ₹643.39 crore | ₹761.17 crore | ₹718.34 crore | PEAK₹2,352.52 crore | ₹418.81 crore |
| Profit Before Tax | ₹643.39 crore | ₹387.77 crore | ₹534 crore | PEAK₹967.40 crore | ₹95.58 crore |
| Tax Expense | ₹160.56 crore | ₹86.45 crore | ₹130.77 crore | PEAK₹356.97 crore | ₹48.61 crore |
Exchange disclosures and regulatory announcements for Glenmark Pharmaceuticals.
On September 10, 2026, India Ratings and Research upgraded Glenmark Pharmaceuticals Ltd's long-term bank loans to 'IND AA+' with a Stable Outlook from 'IND AA', while affirming short-term loans at 'IND A1+'. This rating action follows the company's recognition of USD560 million in revenue from its July 2025 ISB 2001 licensing agreement with AbbVie Inc., which enabled Glenmark to achieve zero gross debt by FYE26. The agency also assigned ratings to additional bank loan facilities totaling INR42 billion (INR18.5 billion and INR23.5 billion) issued under RBI regulation.
On September 11, 2026, Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, announced the commercial launch of RYALTRIS® Nasal Spray in Brazil for treating moderate to severe allergic rhinitis. The product received prior regulatory approval from the Brazilian Health Regulatory Agency (ANVISA) earlier in 2026 and represents the first olopatadine-containing intranasal combination therapy available in the country. This expansion extends access to the dual-action treatment, which is already approved in 57 global markets including the United States and European Union.
Glenmark Pharmaceuticals Limited held its 48th Annual General Meeting on September 11, 2026, via video conferencing to approve financial statements for the fiscal year ended March 31, 2026, and declare a dividend of INR 2.50 per equity share. The meeting also resulted in the re-appointment of Mrs. Blanche Saldanha as a Non-Executive Director and the ratification of remuneration for the Cost Auditor for the year ending March 31, 2027. All resolutions were passed with overwhelming support, receiving over 95% approval from valid votes cast through remote e-voting and electronic voting during the meeting.
Glenmark Pharmaceuticals Limited held its AGM on 2026-09-11 with 81.60% of votes polled on outstanding shares. Shareholders adopted the audited standalone (99.92% in favour) and consolidated (95.88% in favour) financial statements for the year ended March 31, 2026, declared a dividend of INR 2.50 per equity share (99.99% in favour), re-appointed Non-Executive Director Mrs. Blanche Saldanha (99.77% in favour), and ratified the Cost Auditor's remuneration (99.99% in favour).
Glenmark Pharmaceuticals Inc., USA launched Calcium Gluconate Injection USP in three presentations (1,000 mg/10 mL, 5,000 mg/50 mL Single-Dose Vials, and 10,000 mg/100 mL Pharmacy Bulk Package) on August 21, 2026. The product is bioequivalent and therapeutically equivalent to Fresenius Kabi USA, LLC's reference listed drug (NDA 208418). According to IQVIA data for the 12 months ending June 2026, the market for these presentations achieved annual sales of approximately $69.9 million.
Glenmark Pharmaceuticals and its U.S. unit received U.S. FDA approval on August 20, 2026, for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray, a bioequivalent and therapeutic equivalent to Flonase® Nasal Spray. The product will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. The reference listed drug Flonase® Nasal Spray market achieved annual sales of approximately $295.2 million for the 12-month period ending June 2026, according to IQVIA® data.
Glenmark Pharmaceuticals Limited announced the 48th Annual General Meeting scheduled for September 11, 2026, at 2:00 p.m., to be conducted via Video Conferencing or Other Audio-Visual Means. The public notice regarding this meeting was published in the Financial Express and Loksatta newspapers on August 15, 2026, pursuant to the Companies Act, 2013, and Ministry of Corporate Affairs Circular No. 03/2025. The filing was submitted by Company Secretary Rashmi Khandelwal to the National Stock Exchange and BSE Limited.
Glenmark Pharmaceuticals is sending letters to shareholders without registered email IDs, providing a web-link and QR Code to access the Integrated Annual Report and Notice of the 48th Annual General Meeting (AGM) for FY 2025-26. The AGM is scheduled for September 11, 2026, at 2:00 PM IST via video conference.
Recent market and company developments associated with Glenmark Pharmaceuticals.
Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance.
Glenmark launches RYALTRIS nasal spray in Brazil, offering a dual-action treatment for allergic rhinitis after ANVISA approval.
Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark), today announced the launch of RYALTRIS Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older.
Sensex Today, Nifty 50 | Stock Market Highlights - Find here all the highlights related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 11 September 2026
India Business News: Top stock market recommendations: Bank of Maharashtra, Glenmark Pharma, and Tata Technologies have been shared as the top stocks to buy today on Septe.
At 12:30 IST, the barometer index, the S&P BSE Sensex gained 48.27 points or 0.06% to 77,585.99. The Nifty 50 index jumped 13.45 points or 0.05% to 24,244.55.
Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Sai Life Sciences,Shriram Finance,EID Parry (India),Raymond,Glenmark Pharmaceuticals,Multi Commodity Exchange of India,
Key equity benchmarks staged a strong rebound on Thursday, with the Nifty snapping a seven-session losing streak and reclaiming the 24,200 level, while the Sensex jumped over 600 points. The recovery was supported by easing US Treasury yields after the US Treasury announced plans to double its buybacks of longer-duration government debt, helping steady global bond markets and improve risk appetite. Buying was broad-based, led by IT, financials, realty and media stocks, while the broader market also ended higher. The rupee snapped its three-day losing streak and closed at 95.71 per dollar. Technically, the Nifty faces an immediate hurdle at 24,290-24,320, while 24,130-24,100 remains a crucial support zone.
Comprehensive Section Breakdown for Glenmark Pharmaceuticals
Strategic Vision: Global pharmaceutical company advancing science-led therapies.
• Decades of research in dermatology
• Expertise in biologics discovery and early development within oncology
• Established portfolio of over 120 dermatological products
Glenmark Pharmaceuticals reported revenue of ₹4,018.48 crore for the quarter ended 30 June 2026 (FY2026-27 Q1), a 23% increase from the same period last year. Reported net profit climbed to ₹482.83 crore, driven largely by the absence of large pre-tax charges that reduced earnings in the prior year. Underlying profit before exceptional items grew 54% year over year. On a sequential basis, revenue increased modestly, but underlying profitability fell as total expenses rose faster than top-line income.
Revenue from operations for the quarter ended 30 June 2026 stood at ₹4,018.48 crore. This represents a 6.57% increase from the preceding quarter (March 2026) and a 23.1% increase from the year-ago quarter (June 2025).
Over the five available quarters, the September 2025 period stands as a distinct outlier with revenue of ₹6,046.87 crore, approximately 50% higher than the current quarter. Excluding that single period, the current quarter reflects the highest revenue level recorded in the series. The sequence has moved from ₹3,264.44 crore in June 2025, spiked to ₹6,046.87 crore in September 2025, settled around ₹3,770–₹3,900 crore in late 2025, and returned to ₹4,018.48 crore in the current quarter.
Financial results show a clear divergence between underlying operating performance and reported pre-tax profit due to non-recurring items.
Underlying profit before exceptional items and tax (PBEIT) increased to ₹643.39 crore in the current quarter. Compared to the year-ago quarter, this represents a 53.6% increase. However, compared to the immediately preceding quarter, PBEIT decreased by 15.5% from ₹761.17 crore.
In the current quarter, reported profit before tax (PBT) matched PBEIT at ₹643.39 crore, indicating no exceptional items were recognized below the pre-exceptional line. In contrast, the year-ago quarter showed a significant gap: PBEIT was ₹418.81 crore while PBT was only ₹95.58 crore. This difference of ₹323.23 crore reflects substantial exceptional charges deducted in the prior year.
The reported 573% year-over-year increase in PBT is therefore amplified by the removal of these prior-year charges. The increase in underlying profit contributed ₹224.6 crore to the total growth, while the reduction in the exceptional-item gap contributed ₹323.2 crore, together accounting for the full ₹547.8 crore increase in reported PBT.
While revenue and total income both grew sequentially, underlying profitability declined, indicating that total costs expanded faster than top-line sales.
Other expenses increased by 8.96% quarter-on-quarter to ₹1,033.19 crore, outpacing the 6.57% revenue growth. Finance costs rose by 26.74% to ₹54 crore, though the absolute amount remains small relative to revenue.
Total income (revenue plus other income) grew by ₹124.58 crore sequentially, rising from ₹3,959.67 crore to ₹4,084.25 crore. Despite this income growth, PBEIT fell by ₹117.78 crore. The combined increase in other expenses and finance costs accounts for only a portion of this profit decline, meaning other operating costs also rose during the period. The sequential drop in underlying profit highlights that cost expansion exceeded revenue gains.
Tax expense for the quarter was ₹160.56 crore, an 85.7% increase from the preceding quarter and a 230% increase from the year-ago quarter. The effective tax rate on reported pre-tax profit was approximately 25% (₹160.56 crore divided by ₹643.39 crore). This aligns closely with the rates observed in the third and fourth quarters of the prior fiscal year (approximately 24.5% and 22.3%), though it is higher than the rate calculated on the depressed pre-tax profit of the year-ago quarter.
Net profit from continuing operations reached ₹482.83 crore, up 60.2% from the March quarter and 927.9% from the year-ago quarter. Basic and diluted earnings per share were both ₹17.11. Dividing net profit by basic earnings per share yields an implied share count of approximately 28.2 crore, which remains stable across the reported periods.
Comprehensive income for the period was ₹523.28 crore, exceeding net profit by ₹40.45 crore. This pattern—where comprehensive income exceeds net profit—has persisted across all five quarters shown, indicating consistent positive other comprehensive income. The magnitude of this addition was lower in the current quarter compared to the March quarter, where the gap was nearly ₹189 crore.
The quarter delivered substantially higher earnings than the same period last year, with revenue growing 23% and net profit surging nearly tenfold. However, the headline profit growth is amplified by the fact that the prior year included large pre-tax charges that are absent this year. When looking at underlying profit before exceptional items, growth was more moderate at 54% year over year. Sequentially, the company generated more revenue but less underlying profit, as expenses grew faster than sales during the quarter.
Category: Pharmaceuticals
Glenmark's Oncology portfolio concentrates on advancing therapies for solid tumors and hematological malignancies, leveraging deep disease understanding and global collaborations.
Key Products & Services: Envafolimab (QinHayo®) • Tislelizumab (TEVIMBRA®) • Zanubrutinib (Brukinsa®) • Trastuzumab Rezetecan (SHR-A1811) • Aumolertinib
Category: Pharmaceuticals
In the Respiratory segment, Glenmark addresses chronic conditions like asthma, COPD, and common ailments, offering advanced devices and therapies.
Key Products & Services: Ryaltris®
Category: Pharmaceuticals
Dermatology is a foundational and strategically important therapeutic area with over four decades of research and more than 120 products.
Core Thesis: Glenmark's approach to innovation involves therapeutic focus, scientific rigor, and global partnerships to accelerate access to next-generation therapies.
• Therapeutic Focus: The company focuses on advancing differentiated, science-led therapies in Respiratory, Dermatology, and Oncology. • Scientific Rigor: The company emphasizes scientific rigor in its approach to developing therapies. • Global Partnerships: Global partnerships are leveraged to accelerate access to therapies and expand capabilities. • Accessibility: Emphasis on accessibility through scalable manufacturing, fair pricing, and differentiated delivery formats.